1. T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1.
- Author
-
Trad, Malika, Gautheron, Alexandrine, Fraszczak, Jennifer, Alizadeh, Darya, Larmonier, Claire, LaCasse, Collin J., Centuori, Sara, Audia, Sylvain, Samson, Maxime, Ciudad, Marion, Bonnefoy, Francis, Lemaire-Ewing, Stéphanie, Katsanis, Emmanuel, Perruche, Sylvain, Saas, Philippe, and Bonnotte, Bernard
- Subjects
- *
ANIMAL experimentation , *ANTIGENS , *BIOLOGICAL models , *CYTOKINES , *ENZYMES , *FLOW cytometry , *HIGH performance liquid chromatography , *IMMUNOGLOBULINS , *MICE , *T cells , *TUMORS , *WESTERN immunoblotting , *DESCRIPTIVE statistics , *MANN Whitney U Test - Abstract
T lymphocytes activated by dendritic cells (DC) which present tumor antigens play a key role in the antitumor immune response. However, in patients suffering from active cancer, DC are not efficient at initiating and supporting immune responses as they participate to T lymphocyte inhibition. DC in the tumor environment are functionally defective and exhibit a characteristic of immature phenotype, different to that of DC present in nonpathological conditions. The mechanistic bases underlying DC dysfunction in cancer responsible for the modulation of T-cell responses and tumor immune escape are still being investigated. Using two different mouse tumor models, we showed that tumor-infiltrating DC (TIDC) are constitutively immunosuppressive, exhibit a semimature phenotype, and impair responder T lymphocyte proliferation and activation by a mechanism involving CD39 ectoenzyme. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF